Amphastar Pharmaceuticals (AMPH) & The Competition Financial Comparison

Amphastar Pharmaceuticals (NASDAQ: AMPH) is one of 114 publicly-traded companies in the “Pharmaceuticals” industry, but how does it contrast to its peers? We will compare Amphastar Pharmaceuticals to related businesses based on the strength of its earnings, valuation, risk, dividends, profitability, institutional ownership and analyst recommendations.

Risk & Volatility

Amphastar Pharmaceuticals has a beta of 1.69, suggesting that its stock price is 69% more volatile than the S&P 500. Comparatively, Amphastar Pharmaceuticals’ peers have a beta of 0.88, suggesting that their average stock price is 12% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings for Amphastar Pharmaceuticals and its peers, as reported by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Amphastar Pharmaceuticals 0 1 5 0 2.83
Amphastar Pharmaceuticals Competitors 806 3577 6173 156 2.53

Amphastar Pharmaceuticals presently has a consensus price target of $20.17, indicating a potential upside of 7.84%. As a group, “Pharmaceuticals” companies have a potential upside of 22.10%. Given Amphastar Pharmaceuticals’ peers higher probable upside, analysts clearly believe Amphastar Pharmaceuticals has less favorable growth aspects than its peers.

Earnings and Valuation

This table compares Amphastar Pharmaceuticals and its peers revenue, earnings per share and valuation.

Gross Revenue EBITDA Price/Earnings Ratio
Amphastar Pharmaceuticals $249.62 million $17.41 million 233.78
Amphastar Pharmaceuticals Competitors $8.02 billion $2.61 billion 0.18

Amphastar Pharmaceuticals’ peers have higher revenue and earnings than Amphastar Pharmaceuticals. Amphastar Pharmaceuticals is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.


This table compares Amphastar Pharmaceuticals and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Amphastar Pharmaceuticals 1.61% 2.42% 1.84%
Amphastar Pharmaceuticals Competitors -3,036.76% -54.42% -9.10%

Insider and Institutional Ownership

44.3% of Amphastar Pharmaceuticals shares are owned by institutional investors. Comparatively, 43.7% of shares of all “Pharmaceuticals” companies are owned by institutional investors. 11.1% of Amphastar Pharmaceuticals shares are owned by insiders. Comparatively, 12.1% of shares of all “Pharmaceuticals” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.


Amphastar Pharmaceuticals beats its peers on 8 of the 13 factors compared.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company focuses primarily on developing, manufacturing, marketing and selling generic and injectable, inhalation and intranasal products. The Company has two segments: finished pharmaceutical products and active pharmaceutical ingredients (API) products. The finished pharmaceutical products segment manufactures, markets and distributes enoxaparin, Cortrosyn, Amphadase, naloxone, lidocaine jelly, as well as various other critical and non-critical care drugs. The API segment manufactures and distributes recombinant human insulin and porcine insulin. The Company also manufactures and sells insulin API. As of December 31, 2016, the Company manufactured and sold 19 products. As of December 31, 2016, the Company developed a portfolio of 15 generic abbreviated new drug applications (ANDAs) three generic biosimilar product candidates and six injectable and inhalation product candidates.

What are top analysts saying about Amphastar Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Amphastar Pharmaceuticals Inc. and related companies.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit